Shanghai Obio Technology (688238) News

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Yahoo FinanceMay 13 04:18

HeYuan Bio: First Quarter Report for 2026

SZSIApr 28 00:00 · Announcements

First Quarter Report for 2026

SZSIApr 28 00:00 · Announcements

Heyuan Biotech (688238.SH) reported a net loss of 53.0848 million yuan in the first quarter.

Gelonghui reported on April 27 that Heyuan Bio (688238.SH) released its Q1 2026 financial report, showing that the company achieved operating revenue of 50.5405 million yuan in the first quarter, a year-on-year decrease of 4.37%; net profit attributable to shareholders of -53.0848 million yuan; and non-GAAP net profit attributable to shareholders of -54.0122 million yuan.

Gelonghui FinanceApr 27 17:09

Heyuan Biotech (688238): CDMO Orders and Pipeline Progressing Steadily; Cost Reduction and Efficiency Improvement Show Results

The company’s 2025 performance met our expectations. The company announced its 2025 results: revenue reached RMB 268 million, representing a year-on-year increase of 7.88%; gross profit showed a loss of RMB 39 million; net profit attributable to shareholders recorded a loss of RMB 235 million, with the loss narrowing year-on-year.

CICCApr 21 14:07

Heyuan Biotechnology's losses narrowed in 2025, but the gross margin of its CDMO business has yet to turn positive.

①The CRO business is relatively mature, with a stable gross profit margin, whereas the CDMO business involves high technical difficulty. Its gross profit margin correlates with the execution phase and is further influenced by commercial opportunity considerations, exhibiting inherent volatility. ②The short-term competitive landscape in the cell and gene therapy CRO/CDMO industry remains intense, and recovery from price competition for outsourcing orders will take time.

cls.cnApr 21 09:36

Shanghai Obio Technology: Summary of the Annual Report for 2025

SZSIApr 21 00:00 · Announcements

Shanghai Obio Technology: Annual Report 2025

SZSIApr 21 00:00 · Announcements

Annual Report 2025

SZSIApr 21 00:00 · Announcements

Summary of the 2025 Annual Report

SZSIApr 21 00:00 · Announcements

Heyuan Biotech (688238.SH) reported its 2025 annual performance, with a net loss attributable to shareholders of 235 million yuan.

Heyuan Biotechnology (688238.SH) disclosed its annual report for 2025. During the reporting period, the company achieved revenue of 268 million yuan, representing a year-on-year increase of 7.88%. The net loss attributable to shareholders of the listed company amounted to 235 million yuan, showing a narrowing year-on-year. The non-recurring net loss was 246 million yuan, also narrowing year-on-year. The basic earnings per share were -0.370 yuan.

Zhitong FinanceApr 20 18:24

Heyuan Biotechnology (688238.SH) plans to manage its cash using up to 300 million yuan of its own funds.

Gelonghui, April 20th - Hoyo Biotech (688238.SH) announced that the company plans to use up to RMB 300 million (inclusive) of its own funds for cash management. The approved quota for cash management will be valid for 12 months from the date of board approval and can be used on a rolling basis.

Gelonghui FinanceApr 20 17:18

Express News | Heyuan Biotech: The company name change has been registered with the authorities, and a new business license has been issued.

BreakingsMar 2 18:17

HeYuan Bio: Announcement of the 2025 Annual Performance Quick Report

SZSIFeb 27 00:00 · Announcements

2025 Annual Performance Quick Report Announcement

SZSIFeb 27 00:00 · Announcements

Express News | Heyuan Biotech: Net loss of 101.0973 million yuan year-on-year in 2025

BreakingsFeb 26 17:23

Heyuan Biotech (688238.SH): Plans to invest up to 100 million yuan to establish an industrial M&A fund.

Gelonghui, February 5th丨Hollybio (688238.SH) announced that the cell and gene therapy sector, as one of the most groundbreaking frontier fields, has become a core growth point for the global healthcare industry due to its revolutionary therapeutic potential. It is currently at a critical juncture of technological breakthroughs and industrial transformation. Guided by national industrial development policies, in order to better support the company’s medium- and long-term strategic layout in the gene and cell therapy industry, enhance its sustainable competitive capabilities, and strengthen industrial synergies, while ensuring the development of its main business operations, the company plans to collaborate with Shanghai Hongsheng Junhao Equity Investment Fund Management Co., Ltd. (referred to as “

Gelonghui FinanceFeb 5 17:29

HeYuan Bio: Announcement of Estimated Annual Loss for 2025

SZSIJan 28 00:00 · Announcements

2025 Annual Performance Loss Forecast Announcement

SZSIJan 28 00:00 · Announcements

Time as a Witness, Value in Tandem – The 2025 THINKER Finance Investor Summit and the 18th Anniversary Celebration of Achievements and Glory concluded successfully.

On January 7, 2026, the 2025 Investors Annual Conference hosted by Sirui Finance, themed 'Time as a Witness, Value in Tandem,' along with the 18th Anniversary Celebration of Achievements and Glory, successfully concluded at the Pudong Star River Bay Hotel in Shanghai. The conference brought together nearly two hundred representatives from financial institutions and listed companies nationwide to celebrate this grand occasion, paying tribute to Sirui Finance's 18 years of dedication while exploring new opportunities amid the changing times. With unwavering初心 (original aspiration), the platform has remained committed to information transparency over the past 18 years. At the start of the event, Ms. Wu Yue, Executive Editor-in-Chief of Investor Network & Sirui Finance, reflected on the platform's 18-year journey in sync with China’s economic development. She highlighted that from in-depth reporting during the print media era to adapting to the digital age, the organization has continuously evolved.

China InvestorsJan 8 17:10